Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03449134 · ClinicalTrials.gov registry record · Phase 3
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
NCT03449134 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 732 participants.
The verdict
NCT03449134, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
Study Summary
The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12.
Interventions
- DRUG Placebo
- DRUG Gefapixant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03449134
The ClinicalTrials.gov registry entry for NCT03449134 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03449134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03449134 about?
NCT03449134 is a clinical study titled "A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)". The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is superior to placebo in ...
What is the current status of trial NCT03449134?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2018-03-14. Estimated completion is 2020-08-17.
What interventions are being tested in trial NCT03449134?
The interventions under investigation include: Placebo (DRUG), Gefapixant (DRUG).
Who is sponsoring clinical trial NCT03449134?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.